Q4 2017 EPS Estimates for Aurinia Pharmaceuticals Inc Lowered by Seaport Global Securities (TSE:AUP)

Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Equities research analysts at Seaport Global Securities decreased their Q4 2017 EPS estimates for shares of Aurinia Pharmaceuticals in a research note issued on Wednesday, Zacks Investment Research reports. Seaport Global Securities analyst V. Bernardino now forecasts that the company will post earnings per share of ($0.10) for the quarter, down from their prior forecast of ($0.05). Seaport Global Securities currently has a “Buy” rating on the stock. Seaport Global Securities also issued estimates for Aurinia Pharmaceuticals’ FY2019 earnings at ($0.24) EPS and FY2020 earnings at ($0.11) EPS.

Aurinia Pharmaceuticals (AUP) traded down C$0.07 during mid-day trading on Friday, reaching C$6.71. The company’s stock had a trading volume of 43,823 shares, compared to its average volume of 122,920. Aurinia Pharmaceuticals has a twelve month low of C$2.75 and a twelve month high of C$14.17.

COPYRIGHT VIOLATION NOTICE: “Q4 2017 EPS Estimates for Aurinia Pharmaceuticals Inc Lowered by Seaport Global Securities (TSE:AUP)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/04/q4-2017-eps-estimates-for-aurinia-pharmaceuticals-inc-reduced-by-analyst-aup.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply